+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
E

Actively Recruiting

Researchers are evaluating JADE101, a drug administered by subcutaneous injection, for adults with immunoglobulin A nephropathy IgAN in this Phase 3 study. The trial compares the safety and effectiveness of JADE101 against a placebo to help better understand its impact on this kidney condition. The study is sponsored by Jade Biosciences, Inc. and aims to assess the drugs effect on protein levels in urine and kidney function. Participants will receive either JADE101 with maintenance doses every 8 weeks or every 12 weeks, or a placebo injection during the placebo-controlled treatment period. JADE101 and placebo are both given via subcutaneous injections. The study uses a randomized, double-blind design to fairly compare the groups, and treatment will continue for a specified period with regular dosing. During the trial, participants will have their urine protein creatinine ratio UPCR and estimated glomerular filtration rate eGFR measured at week 52 to evaluate kidney function and disease progression. Safety and efficacy will be monitored throughout the study, which is expected to last until September 2030. Participants must meet specific eligibility criteria including confirmed diagnosis, proteinuria levels, kidney function, and stable use of standard medications.

Age: 18Years +All GendersPhase 3
4 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.

Age: 18Years - 130YearsAll GendersPhase 3
152 locations
E

Actively Recruiting

Researchers are studying JADE101, a drug administered by subcutaneous injection, to evaluate its safety and effectiveness in adults with Immunoglobulin A nephropathy IgAN, a kidney condition. This open-label Phase 2 trial aims to better understand how JADE101 works in this patient group and contributes to ongoing clinical knowledge. The study is sponsored by Jade Biosciences, Inc. Participants will receive JADE101 through subcutaneous injections. All participants receive the same treatment without a comparison group. The study will monitor participants from Day 1 through 100 weeks to assess safety and effects on urine protein levels. There is no placebo or blinding in this trial. During the study, participants will attend scheduled visits and undergo laboratory tests to monitor kidney function and protein levels in urine. Researchers will track any treatment-emergent side effects and changes in urine protein creatinine ratio to evaluate the drugs impact. Participants must comply with treatment plans and contraceptive and lifestyle requirements throughout the trial, which lasts approximately 100 weeks.

Age: 18Years - 60YearsAll GendersPhase 2
22 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of praliciguat in adults diagnosed with biopsy-confirmed focal segmental glomerulosclerosis FSGS, a kidney disease. This Phase 2, randomized, double-blind, placebo-controlled, multicenter study compares praliciguat to a placebo over an initial 24-week period, followed by an open-label phase where all participants receive praliciguat for another 24 weeks. Those who respond to treatment may join a long-term safety extension study. Participants are randomly assigned to receive either praliciguat or a matching placebo daily during the 24-week double-blind period. After this, all participants take praliciguat daily during the 24-week open-label period. Dose escalation to a target dose occurs during the initial treatment phase. Responders are invited to continue in a long-term safety extension where praliciguat is administered daily. During the study, participants undergo regular assessments including urine protein-to-creatinine ratio UPCR measurements, monitoring for treatment-emergent adverse events, and plasma concentration tests of praliciguat. Safety is closely tracked through reports of adverse events during both treatment periods and the long-term extension. The total participation duration may extend up to more than 48 weeks depending on extension study enrollment.

Age: 18Years +All GendersPhase 2
30 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
A

Actively Recruiting

Researchers are evaluating povetacicept for its efficacy, safety, and tolerability in people with primary membranous nephropathy pMN, a kidney condition. This Phase 2b3 adaptive, randomized study compares povetacicept with the calcineurin inhibitor tacrolimus to determine which treatment better supports clinical remission of pMN. Participants will be randomly assigned to receive one of two doses of povetacicept, given as a subcutaneous injection, or tacrolimus capsules taken orally. The study includes sequential phases, with dosing based on previous phase results. Participants will receive their assigned treatment and be monitored throughout the study. During participation, individuals will be assessed for clinical remission at 104 weeks, and safety will be monitored up to 112 weeks by tracking adverse events. Researchers will conduct regular evaluations to measure how well the treatments work and their tolerability. The total study duration extends up to nearly four years, with ongoing monitoring and data collection.

Age: 18Years - 75YearsAll GendersPhase 2Phase 3
117 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness and safety of LUPKYNIS combined with belimumab, obinutuzumab, or anifrolumab in adults with lupus nephritis LN. The study focuses on how well these combinations induce a rapid kidney response in patients diagnosed with LN, a condition affecting kidney health. It is a phase 4 clinical trial sponsored by Aurinia Pharmaceuticals Inc. that assesses treatment approaches for this condition. Participants will receive LUPKYNIS along with one of the biologic agents belimumab, obinutuzumab, or anifrolumab. In addition, all patients will be treated with a mycophenolic acid analog MPAA, such as mycophenolate mofetil or mycophenolic acid, and corticosteroids like prednisone or an equivalent. The biologic treatment schedules vary depending on the specific drug, with some patients already receiving treatment before the study starts or beginning it at the start of the trial. During the study, participants will be monitored for kidney response over 24 weeks, including complete and partial renal responses. Researchers will assess safety by tracking treatment-emergent adverse events up to 28 weeks. Other assessments include measuring changes in kidney-related antibodies and complement levels at baseline, 12 weeks, and 24 weeks. The total participation duration extends to about 28 weeks, during which various evaluations, laboratory tests, and safety monitoring will occur to understand treatment effects and patient outcomes.

Age: 18Years - 75YearsAll GendersPhase 4
27 locations

1-10 of 12

1